results

HUTCHMED to Announce 2025 Half-Year Financial Results

July 03, 2025 04:30 ET  | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03,…

8 hours ago

Hyundai Motor Group Tops 2025 J.D. Power U.S. Initial Quality Study

Hyundai Motor Group ranks No.1 among all corporations in the J.D. Power 2025 U.S. Initial Quality Study for the second…

10 hours ago

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646…

1 day ago

Radware Schedules Conference Call for Its Second Quarter 2025 Earnings

TEL AVIV, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR), a global leader in application security and delivery…

1 day ago

Kia Announces June 2025 Global Sales Results

June 2025 global sales of 269,652 units, up 0.2% Y/yOutside of Korea, Kia sold 222,997 units, down 0.8% Y/yKia RVs…

1 day ago

Rockefeller Foundation Supports BRAC to Empower Smallholder Farmers Across Asia and Africa

Through the 300,000 USD grant, BRAC will develop a program that aims to empower three million women smallholder farmers across…

1 day ago

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for…

2 weeks ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of…

2 weeks ago

Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…

2 weeks ago